10-Q

(redirected from Form 10Q)

10-Q

Quarterly report required by the SEC each quarter. Provides a comprehensive overview of a company's state of business.

10-Q

A form the SEC requires publicly-traded companies and some private companies to file every quarter. It includes statements on equity and unaudited financial statements. While similar to a shareholder report, a 10-Q form often contains more information, such as executive compensation and organizational structure. All publicly-traded companies and any privately traded companies with more than 500 shareholders and $10 million in assets are required to file a 10-Q. Companies only file three 10-Q forms each year, as the final quarter's numbers are included in the 10-K. See also: Transparency.

10-Q

A quarterly unaudited financial report filed by firms that have securities listed with the SEC. The 10-Q is a less detailed, more frequently filed version of the 10-K. Also called Form 10-Q.
References in periodicals archive ?
OTC:TEWI), a company involved in distributed power generation products and intelligent energy management services, has filed its amended Form 10Q for the period ending September 30, 2011.
NASDAQ:WAVE) today announced that it has filed its Quarterly Report on Form 10Q with the Securities and Exchange Commission for the fiscal quarter of fiscal 2009, ended March 28, 2009.
The Form 10Q is available on the web site maintained by the Securities and Exchange Commission at www.
For a detailed discussion of these and other risk factors, interested parties should review the Company's filings with the Securities and Exchange Commission, including the Company's Form 10-K filed on December 14, 2005, the Company's Form 10Q filed on February 9, 2006, the Company's Form 10Q filed on May 10, 2006, and the Company's Form 10Q filed on August 9, 2006.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's annual report on Form 10K for the year ended December 31, 2005 and quarterly report on Form 10Q for the period ended September 30, 2006, as filed with the Securities and Exchange Commission, which "Risk Factors" discussion is incorporated by reference in this release.
NEW YORK -- Fitch Ratings has placed KB Home's ratings on Rating Watch Negative (RWN) due to the company's inability to make a timely filing of its Form 10Q (for the quarter ended August 31, 2006) with the Securities and Exchange Commission and consequent need to negotiate waivers with its banks and seek a similar consent from the senior unsecured bond holders.
On October 18, 2006, the company entered into an amendment to its Revolving Credit Agreement and its Term Loan Agreement extending the time period for delivering its Form 10Q for the quarter ended August 31, 2006 to December 24, 2006.
The Partnership files documents with the Securities and Exchange Commission, such as Form 10-K, Form 10Q and Form 8-K reports, which contain a description of these and other risks and uncertainties that could cause actual results to differ from current expectations and the forward-looking statements contained in this press release.
Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's annual report on Form 10K for the year ended December 31, 2005 and quarterly report on Form 10Q for the period ended July 1, 2006, as filed with the Securities and Exchange Commission, which "Risk Factors" discussion is incorporated by reference in this release.
Factors that could cause actual results to differ materially from expectations include financial performance, regulatory changes, changes in local or national economic conditions and other risks detailed from time to time in the Company's reports filed with the SEC, including quarterly reports on Form 10Q, reports on Form 8-K and annual reports on Form 10-K.
The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to those related to our expectations regarding our license arrangement with Esprit Pharma; the conclusion of our discussions with Esprit Pharma; research and development efforts, including pre-clinical and clinical testing; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K and its most recent Quarterly Report on Form 10Q.